» Articles » PMID: 26485028

Antigenic Characterization of the HCMV GH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies

Abstract

Human Cytomegalovirus (HCMV) is a major cause of morbidity and mortality in transplant patients and in fetuses following congenital infection. The glycoprotein complexes gH/gL/gO and gH/gL/UL128/UL130/UL131A (Pentamer) are required for HCMV entry in fibroblasts and endothelial/epithelial cells, respectively, and are targeted by potently neutralizing antibodies in the infected host. Using purified soluble forms of gH/gL/gO and Pentamer as well as a panel of naturally elicited human monoclonal antibodies, we determined the location of key neutralizing epitopes on the gH/gL/gO and Pentamer surfaces. Mass Spectrometry (MS) coupled to Chemical Crosslinking or to Hydrogen Deuterium Exchange was used to define residues that are either in proximity or part of neutralizing epitopes on the glycoprotein complexes. We also determined the molecular architecture of the gH/gL/gO- and Pentamer-antibody complexes by Electron Microscopy (EM) and 3D reconstructions. The EM analysis revealed that the Pentamer specific neutralizing antibodies bind to two opposite surfaces of the complex, suggesting that they may neutralize infection by different mechanisms. Together, our data identify the location of neutralizing antibodies binding sites on the gH/gL/gO and Pentamer complexes and provide a framework for the development of antibodies and vaccines against HCMV.

Citing Articles

The Pentamer glycoprotein complex inhibits viral Immediate Early transcription during Human Cytomegalovirus infections.

Ohman M, Albright E, Gelbmann C, Kalejta R Proc Natl Acad Sci U S A. 2024; 121(39):e2408078121.

PMID: 39292744 PMC: 11441559. DOI: 10.1073/pnas.2408078121.


A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation.

Atanasoff K, Parsons A, Ophir S, Lurain N, Kraus T, Moran T J Virol. 2024; 98(7):e0021324.

PMID: 38832789 PMC: 11264687. DOI: 10.1128/jvi.00213-24.


Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.

Wu K, Hou Y, Makrinos D, Liu R, Zhu A, Koch M J Virol. 2024; 98(4):e0160323.

PMID: 38526054 PMC: 11019844. DOI: 10.1128/jvi.01603-23.


An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection.

Panda K, Parashar D, Viswanathan R Viruses. 2023; 15(6).

PMID: 37376657 PMC: 10303229. DOI: 10.3390/v15061358.


Neutralization Epitopes in Trimer and Pentamer Complexes Recognized by Potent Cytomegalovirus-Neutralizing Human Monoclonal Antibodies.

Ai Y, Wu C, Zhang M, Jaijyan D, Liu T, Zan L Microbiol Spectr. 2022; 10(6):e0139322.

PMID: 36342276 PMC: 9784774. DOI: 10.1128/spectrum.01393-22.


References
1.
Backovic M, Longnecker R, Jardetzky T . Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci U S A. 2009; 106(8):2880-5. PMC: 2650359. DOI: 10.1073/pnas.0810530106. View

2.
Wen Y, Monroe J, Linton C, Archer J, Beard C, Barnett S . Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine. 2014; 32(30):3796-804. DOI: 10.1016/j.vaccine.2014.05.004. View

3.
Nokta M, Tolpin M, Nadler P, Pollard R . Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res. 1994; 24(1):17-26. DOI: 10.1016/0166-3542(94)90048-5. View

4.
Sung H, Schleiss M . Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010; 9(11):1303-14. PMC: 3595507. DOI: 10.1586/erv.10.125. View

5.
Saccoccio F, Sauer A, Cui X, Armstrong A, Habib E, Johnson D . Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine. 2011; 29(15):2705-11. PMC: 3084484. DOI: 10.1016/j.vaccine.2011.01.079. View